DS
ACHN

DRW Securities’s Achillion Pharmaceuticals ACHN Stock Holding History

DRW Securities’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-53,206
Closed -$129K – 271
2013
Q3 		$129K Buy
+53,206
New +$365K 0.01% 148

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

DRW Securities's ACHN Position: Q4 2013 in Review

DRW Securities sold out of Achillion Pharmaceuticals (ACHN) in Q4 2013, closing a stake of 53,206 shares — an estimated $129K sold.

DRW Securities first reported a position in ACHN in Q3 2013 and held it in 1 quarter. The position peaked at $129K in Q3 2013. 93 funds tracked by Wall St. Rank hold ACHN as of Q4 2013.

  • DRW Securities reported no remaining Achillion Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • DRW Securities sold 53,206 Achillion Pharmaceuticals shares in Q4 2013, an estimated $129K.
  • DRW Securities first reported a position in Achillion Pharmaceuticals in Q3 2013 and held it in 1 quarter.
  • DRW Securities's Achillion Pharmaceuticals position peaked at $129K in Q3 2013.
  • 93 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2013.

Based on DRW Securities's 13F filing for Q4 2013, filed 14 Feb 2014.